Related Experiment Video

Updated: Jan 15, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.4K

Biologics for treatment of paediatric plaque psoriasis: A systematic review and network meta-analysis

Abdullah Ali Aljalfan1, Muhammad Talha Maniya2, Dilshad Sachedina3

  • 1Department of Dermatology, King Fahad University Hospital, Al Khobar, Saudi Arabia.

Journal of the European Academy of Dermatology and Venereology : JEADV
|October 15, 2025
PubMed

Insights

Biologic therapies significantly improve paediatric psoriasis outcomes compared to placebo. While individual agents show trends, no single biologic is definitively superior for moderate-to-severe plaque psoriasis in children.

Area of Science:

  • Dermatology
  • Pharmacology
  • Clinical Trials

Background:

  • Paediatric psoriasis treatment is evolving with increased biologic use.
  • Moderate-to-severe plaque psoriasis in children requires effective therapeutic options.

Purpose of the Study:

  • To systematically review and network meta-analyze biologic treatments for paediatric plaque psoriasis.
  • To compare the efficacy and safety of available biologics in this population.

Main Methods:

  • A systematic search of randomized controlled trials (RCTs) was conducted across major databases.
  • A fixed-effects frequentist network meta-analysis (NMA) was performed.
  • Key outcomes included PASI75, PASI90, PASI100, and CDLQI scores at 12-16 weeks.

Main Results:

  • Seven RCTs involving 1016 patients were analyzed.
  • All biologics demonstrated significantly higher PASI75 and PASI90 responses versus placebo.
  • Ixekizumab led in PASI100, Secukinumab (high dose) in PASI90, and Ustekinumab in PASI75 and CDLQI scores.

Conclusions:

  • Biologic agents are significantly more effective than placebo for paediatric plaque psoriasis.
  • No single biologic agent showed a statistically significant advantage over others.
  • Further large-scale trials are needed to identify optimal treatment strategies.
Abstract

Keywords:
biologicsnetwork meta‐analysispaediatric psoriasispsoriasissystematic review

More Related Videos

Author Spotlight: Exploring ShiDuGao's Multi-Target Approach in Anus Eczema Treatment12:34

Author Spotlight: Exploring ShiDuGao's Multi-Target Approach in Anus Eczema Treatment

Published on: January 12, 2024

1.2K
Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

1.1K

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
490
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
242
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
192
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
252
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
212
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
233